Study of a new drug (161Tb-RAD402) for men with advanced prostate cancer
Part of Cancer clinical trials.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic prostate cancer that is no longer responding to hormone therapy.
- Your cancer shows up on a special PSMA PET scan (more uptake than the liver).
- You have tried at least one type of hormone-blocking drug (like enzalutamide or abiraterone) but your cancer kept growing.
- You are in generally good health (able to care for yourself, ECOG score 0 or 1).
- Your kidney function and blood counts are adequate (no severe anemia, low platelets, or kidney failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This trial tests a new radioactive drug, Terbium-161 PSMA, for men with a type of advanced prostate cancer that has stopped responding to standard treatments. It may be an option if you have not received a similar radioactive drug before.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.